Table 2.
Univariate analysis for grade 3 mucositis in patients receiving radiotherapy for pharyngeal or laryngeal cancer
| Variable | Category (Reference) | OR | 95% CI | p-value |
|---|---|---|---|---|
| Sex | Male (Female) | 0.86 | 0.18 – 4.06 | 0.846 |
| Age | 1.00 | 0.96 – 1.05 | 0.894 | |
| BMI (kg/m2) | 1.04 | 0.93 – 1.16 | 0.521 | |
| Smoking (pack-years) | 1.02 | 1.00 – 1.03 | 0.048 | |
| EOCG PS | > 2 (0 or 1) | 0.17 | 0.02 – 1.43 | 0.103 |
| Diabetes mellitus | With (Without) | 0.79 | 0.28 – 2.20 | 0.653 |
| Primary tumor location | Hypopharynx (Larynx) | 1.18 | 0.38 – 3.71 | 0.775 |
| Stage | III, IV (I, II) | 1.10 | 0.37 – 3.32 | 0.866 |
| Therapy | BRT or CRT (Radiotherapy alone) | 3.27 | 0.67 – 16.00 | 0.145 |
| Radiotherapy method | IMRT (3D-CRT) | 1.43 | 0.63 – 3.21 | 0.393 |
| NLR | 1.09 | 1.02 – 1.16 | 0.016 | |
| Concentration of albumin | 1.42 | 0.62 – 3.24 | 0.404 | |
| Concentration of hemoglobin | 1.07 | 0.84 – 1.35 | 0.593 | |
| Concentration of urea nitrogen | 1.03 | 0.97 – 1.09 | 0.390 | |
| Concentration of creatinine | 0.97 | 0.26 – 3.56 | 0.959 |
Abbreviations: BMI Body mass index, EOCG PS Eastern Cooperative Oncology Group performance status, NLR Neutrophil-to-lymphocyte ratio, BRT Bioradiotherapy (cetuximab with radiotherapy), CRT Chemotherapy (cisplatin or carboplatin with radiotherapy), IMRT Intensity-modulated radiotherapy, 3D-CRT Three-dimensional conformal radiotherapy, OR Odds ratio, and CI Confidence interval